Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP102 vs Avastin with paclitaxel/carboplatin in non-squamous NSCLC
CTR20180147Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Hengrui Therapeutics. Started Mar 2018; status: completed.
02
Drugs
bevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20180147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180147.